WHO ICTRP trial
Study with the objective to find in patients with high-frequency episodic…
EUCTR2021-006176-16-DE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2021-006176-16-DE |
|---|---|
| Public title | Study with the objective to find in patients with high-frequency episodic migraine (patients with 8-14 migraine days/months) signs on head MRI (=neuroimaging biomarkers) and indicators from blood and tear fluid (=laboratory biomarkers) which are linked to a good efficacy of a medication named Galcanezumab |
| Scientific title | Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT) - PREDICT |
| Primary sponsor | Charité - Universitätsmedizin Berlin |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Germany |
| Conditions | High-frequency episodic migraine. MedDRA version: 22.0 Level: LLT Classification code 10082019 Term: Episodic migraine System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] |
| Interventions | Trade Name: Emgality Pharmaceutical Form: Injection |
| Registration date | Apr 4, 2022 |
| Target size | 89 |
| Secondary IDs | I5Q-NS-O001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: